Abstract. In the present study, the aim was to investigate the role of microRNA-1180 (miR-1180) in the growth and apoptosis of prostate cancer, as well as to identify its direct targets. Initially, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to examine the expression of miR-1180 in the prostate cancer tissues and adjacent normal prostate tissues of 30 patients, as well as in DU145 and RWPE-1 cells. Next, DU145 cells were transfected with miR-1180 mimics, and the expression levels of associated proteins were determined by western blot assay. In addition, the role of miR-1180 in the proliferation, apoptosis, invasion and migration of DU145 cells was investigated by MTT, flow cytometry, cell invasion and wound healing assays, respectively. A dual-luciferase reporter assay was also performed to examine whether TNF receptor associated factor 1 (TRAF1) and B-cell lymphoma-2-associated athanogene 2 (BAG2) are direct targets of miR-1180. It was observed that miR-1180 expression was significantly decreased in the prostate cancer tissues compared with the normal prostate tissues, and was also inhibited in DU145 cells compared with RWPE-1 cells. Furthermore, transient overexpression of miR-1180 inhibited the proliferation, migration and invasion, and promoted the apoptosis of DU145 cells, as well as alleviated expression of associated proteins. The dual-luciferase reporter assay confirmed that TRAF1 and BAG2 are direct targets of miR-1180. These results suggested that miR-1180 contributed to prostate cancer by targeting TRAF1/BAG2 and by nuclear factor-κB signaling pathway activation.
Introduction
Prostate cancer was reported to be the most common malignancy affecting males in the United States in 2016, with the highest incidence (21%) and a mortality rate (8%) following that associated with lung and bronchus cancer (1) . The incidence of prostate cancer in China is much lower in comparison with that observed in Europe and America, although an increasing trend has been reported (2) . Tumor invasion and metastasis are the leading causes of mortality in prostate cancer patients (3) . Therefore, it is important to investigate the underlying molecular mechanism of prostate cancer invasion and migration and identify novel therapeutic targets. microRNAs (miRNAs or miRs) are noncoding RNAs with a regulatory function. Recent studies have demonstrated that miRNAs are associated with prostate cancer; for instance, miR-1307 promotes the proliferation of prostate cancer through targeting FOXO3A (4) . In addition, let-7b miRNA modulates macrophage polarization and enhances tumor-associated macrophages, promoting angiogenesis and mobility in prostate cancer (5) . miR-345 and miR-195-5p have also been observed to suppress the migration and invasion in human prostate cancer (6, 7) . Furthermore, recent studies have suggested that miR-1180 serves a key role in hepatocellular carcinoma cells (8, 9) , and involves in the regulation of proliferation, migration and invasion of lung cancer (10) . However, the expression and role of miR-1180 in prostate cancer has yet to be evaluated.
In the present study, the role of miR-1180 in the growth and apoptosis of prostate cancer was investigated. It was predicted that TNF receptor associated factor 1 (TRAF1) and B-cell lymphoma 2 (Bcl-2)-associated athanogene 2 (BAG2) were direct targets of miR-1180 by bioinformatics analysis. Therefore, the present study further determined that the effects of miR-1180 in prostate cancer were potentially exerted by targeting TRAF1 and BAG2. 
Materials and methods

Patient
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA from frozen clinical tissues or cultured cells. The RNA concentration was measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.). The total RNA was then reverse transcribed into complementary DNA (cDNA) using Mir-X™ miRNA First Strand Synthesis kit or M-MLV reverse transcriptase (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's instructions. cDNA was subsequently amplified by qPCR using Mir-X miRNA qRT-PCR SYBR ® Kit or One
Step SYBR PrimeScript™ RT-PCR kit II (Perfect Real Time; Takara Biotechnology Co., Ltd.). U6 served as an internal control for the detection of miR-1180 expression, while GAPDH served as an internal control for the determination of TRAF1 and BAG2 expression levels. The primers used were as follows: miR-1180 forward, 5'-ACA CTC CAG CTG GGT TTC CGG CTC GCG TGG-3' and reverse, 5'-TGG TGT CGT GGA GTC G-3'; U6 forward, 5'-CTC GCT TCG GCA GCA CA-3' and reverse, 5'-AAC GCT TCA CGA ATT TGC GT-3'; TRAF1 forward, 5'-TGA GAG GGG AGT ATG ATG CG-3' and reverse, 5'-GAC GCT GAG CTT AGG TCA GG-3'; BAG2 forward, 5'-ATC AAC GCT AAA GCC AAC GAG-3' and reverse, 5'-CGT CAC TGA TCT GCC TCA TGT-3'; GAPDH forward, 5'-GGA GCG AGA TCC CTC CAA AAT-3' and reverse, 5'-GGC TGT TGT CAT ACT TCT CAT GG-3'. The PCR conditions consist of 8 min of DNA polymerase activation at 95˚C, followed by 40 cycles of 95˚C for 30 sec, 55˚C for 30 sec and 72˚C for 30 sec. The relative expression was calculated using the comparative threshold method (2 -ΔΔCq ) (11) .
Western blot analysis. The cells were lysed by 30-min incubation in radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) on ice.
Following centrifugation at 12,000 x g for 15 min at 4˚C, the protein concentration was measured using the Bradford assay (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Equal amounts of proteins were separated by 8-12% SDS-PAGE and electrotransferred onto nitrocellulose membranes. The membranes were blocked with 5% defatted milk at room temperature for 1 h, and then incubated with appropriate primary antibodies; nuclear factor (NF)-κB (sc-56735), Bcl-2 (sc-509), Bcl-2-associated X protein (Bax; sc-80658), caspase-3 (sc-271759), p21 (sc-136020), phosphorylated retinoblastoma protein (p-Rb; sc-135776), cyclin-dependent kinase 4 (CDK4; sc-70832), CDK6 (sc-7961), cyclin D1 (sc-70899), cyclin A2 (sc-136253), TNF receptor associated factor 1 (TRAF1; sc-271683), Bcl-2-associated athanogene 2 (BAG2; sc-101216) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; sc-293335) (all from Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 1:1,000 at 4˚C for overnight. Subsequently, the membranes were washed with TBST for three times and probed with horseradish peroxidase-conjugated secondary antibodies (1:2,000; Santa Cruz Biotechnology, Inc.) at room temperature for 1 h. The target proteins were detected using BeyoECL Plus kit (Beyotime Institute of Biotechnology). Quantification was performed using ImageJ software (version 1.43; National Institutes of Health, Bethesda, MD, USA).
Cell proliferation assay. Cell proliferation was measured by MTT assay. Briefly, DU145 cells were seeded into 96-well plates (4x10 4 cells/well) and incubated at 37˚C for 48 h after transfection. Subsequently, 20 µl MTT solution was added into each well and incubated for 3 h, followed by the addition of dimethyl sulfoxide to extract the dye. The absorbance of each well was then measured at a wavelength of 570 nm using a microplate reader to assess the cell proliferation.
Flow cytometry analysis. DU145 cells were seeded into 6-well plates (1x10 6 cells/well) and incubated at 37˚C for 48 h after transfection. The cells were harvested with 0.25% trypsin and washed with PBS. Following centrifugation at 1,000 x g for 10 min at 4˚C, the cells were double stained with Annexin V-FITC and propidium iodide (Annexin V-FITC Cell Apoptosis Detection kit; Beyotime Institute of Biotechnology) according to the manufacturer's instructions. The results were then analyzed with Cell Quest software (version 3.1) on a FACSort flow cytometer (both from BD Biosciences, Franklin Lakes, NJ, USA).
Cell invasion assay. In order to examine the cell invasion, a Transwell assay was conducted. Briefly, Transwell inserts were pre-coated with BD Matrigel matrix (BD Bioscience). DU145 cells were transfected with miR-negative control (NC) or miR-1180 mimics for 48 h, and then cells in serum-free medium were plated into the upper chamber (5x10 4 cells/ well), while medium containing 10% FBS was added to the lower chamber. Subsequent to culturing for 24 h at 37˚C, the invading cells in the lower chamber were stained with 0.1% crystal violet (Sigma-Aldrich; Merck KGaA) and counted under a microscope.
Wound healing assay. In order to determine the cell migration ability, DU145 cells were plated in a 6-well plate (1x10 6 cells).
Following overnight incubation at 37˚C, the cells were respectively transfected with miR-NC or miR-1180 mimics. When cell confluence reached 90-100%, wounds were created using a 200 µl pipette tip. Wound healing was observed within the scrape line after 24 h, and images of representative wounds of the cells were captured using a microscope. The results were quantified by ImageJ software (version 1.43; National Institutes of Health).
Dual-luciferase reporter assay. DU145 cells were plated in a 6-well plate (1x10 6 cells). Following overnight incubation at 37˚C, the cells were respectively transfected with miR-NC or miR-1180 mimics for 48 h. Target genes of miR-1180 were predicted using TargetScan (http//www.targetscan. org). To detect the targeting association between miR-1180 and TRAF1 and BAG2 3'-untranslated region (3'-UTR), dual-luciferase reporter assay was performed by using Dual Luciferase Reporter Gene Assay kit (Beyotime Institute of Biotechnology) according to the manufacturer's instructions. Dual-luciferase activity was measured to determine the targeting association between miR-1180 and TRAF1 and BAG2 3'-UTR.
Statistical analysis. All quantified data are represented as the mean ± standard deviation. All statistical analyses were performed using SPSS version 18.0 software (IBM Corp., Armonk, NY, USA). Student's t-test was used for comparisons between groups, while one-way analysis of variance was used for comparisons between multiple groups. A value of P<0.05 was considered to indicate a statistically significant difference.
Results
miR-1180 is downregulated in prostate cancer tissues and cells.
To investigate the role of miR-1180 in prostate cancer, the expression of miR-1180 in prostate cancer tissues and cells was assessed by RT-qPCR. As shown in Fig. 1A , miR-1180 expression in the prostate cancer tissues was significantly reduced when compared with that in adjacent normal prostate tissues. In addition, miR-1180 was markedly downregulated in prostate cancer DU145 cells compared with that in normal prostate RWPE-1 cells (Fig. 1B) . These findings suggest that miR-1180 is downregulated in prostate cancer tissues and cells, and thus may regulate prostate cancer progression.
miR-1180 overexpression inhibits the proliferation of DU145 cells. Overexpression of miR-1180 was performed in DU145
cells to analyze its role in prostate cancer. Transfection with mimics significantly enhanced the expression of miR-1180 (P<0.01), as shown in Fig. 1C . Subsequently, the effect of miR-1180 on cell proliferation was examined by an MTT assay, and the results revealed that miR-1180 overexpression inhibited cell proliferation ( Fig. 2A) .
miR-1180 overexpression promotes apoptosis in DU145 cells.
Flow cytometric and western blot analyses were performed to verify the role of miR-1180 in the apoptosis of DU145 cells transfected with miR-1180. Western blot analysis also suggested that the levels of NF-κB and Bcl-2 protein were inhibited, while the levels of Bax and caspase-3 protein were increased (Fig. 2B) . Flow cytometric analysis also demonstrated that the apoptosis rate of transfected DU145 cells was significantly increased as compared with the control and miR-NC-transfected cells (Fig. 2C) . These results indicated that overexpression of miR-1180 promoted the apoptosis of DU145 cells.
miR-1180 inhibits the expression of cell cycle-associated proteins in DU145 cells. Flow cytometric and western blot
analysis were also performed to determine the role of miR-1180 in the progression of the DU145 cell cycle subsequent to transfection by miR-1180 mimics. Flow cytometric analysis revealed that the cell cycle was arrested at G1 phase following miR-1180 overexpression (Fig. 3A) . Furthermore, western blot analysis identified that the level of p21 protein was upregulated, while the levels of p-Rb, CDK4, CDK6, cyclin D1 and Cyclin A2 protein were downregulated (Fig. 3B) . These data suggested that miR-1180 overexpression arrests the cell cycle in DU145 cells.
miR-1180 inhibits the migration and invasion of DU145 cells.
To further describe the function of miR-1180 in prostate cancer, wound healing and transwell assays were performed to observe the migration and invasion of DU145 cells. As shown in Fig. 4A , overexpression of miR-1180 in DU145 cells led to delayed wound healing and markedly reduced cell migration as compared with the control and miR-NC groups. Furthermore, the transwell assay confirmed that the invasion of DU145 cells was significantly inhibited by miR-1180 overexpression (Fig. 4B) . Taken together, these results revealed that miR-1180 inhibited the prostate cancer cell migration and invasion.
TRAF1 and BAG2 are direct targets of miR-1180.
RT-qPCR analysis demonstrated that the expression levels of TRAF1 and BAG2 mRNA were significantly inhibited by miR-1180 mimic transfection (Fig. 5A ). In addition, western blot analysis revealed that the levels of TRAF1 and BAG2 protein were also inhibited (Fig. 5B) . Through the application of bioinformatics analysis, it was predicted that miR-1180 was able to target the 3'-UTR of TRAF1 and BAG2. Dual-luciferase reporter assay was subsequently performed to investigate whether TRAF1 and BAG2 are direct targets of miR-1180. As shown in Fig. 5C , miR-1180 overexpression significantly the inhibited dual-luciferase activity of 3'UTR-WT of TRAF1 and BAG2. These data suggested that TRAF1 and BAG2 are direct targets of miR-1180.
Discussion
miRNAs regulate tumor growth, epithelial-mesenchymal transition and metastasis, and thus may be potentially novel therapeutic targets in prostate cancer (12) . In the present study, the results demonstrated that miR-1180 was downregulated in tumor tissues and DU145 prostate cancer cells as compared with the expression in normal tissues and RWPE-1 cells, respectively. Thus, this indicated that miR-1180 may be a potential tumor suppressor in prostate cancer. Subsequently, the suppressive effect of miR-1180 on the growth and apoptosis of prostate cancer cells was investigated.
An MTT assay applied in the present study indicated that overexpression of miR-1180 significantly inhibited DU145 cell proliferation. The cell proliferation and cell death largely depend on cell cycle progression and metabolism. CDKs are a group of serine/threonine protein kinases, which coordinate with cyclin to regulate the cell cycle. p21 is a potent CDK inhibitor, which inhibits the activity of cyclin-CDK4/6 complexes, consequently regulating the cell cycle progression. In addition, cyclin-CDK4/6 complexes are known to phosphorylate Rb (13) (14) (15) (16) . In the present study, the results of flow cytometry analysis revealed that miR-1180 may suppress the G0/1 to S phase transition. Subsequent western blot analysis also indicated that miR-1180 overexpression led to the increase of p21 level, and the inhibition of p-Rb, CDK4, CDK6, Cyclin D1 and Cyclin A2 levels. These results confirmed that miR-1180 activated p21 expression and inhibited cell cycle-associated proteins, inducing cell cycle arrest and inhibiting DU145 cell proliferation.
Bcl-2 is one of the most important oncogenes in cell apoptosis. Bax forms a heterodimer with Bcl-2, and functions as an apoptotic activator (17) . In addition, the NF-κB signaling pathway is involved in numerous cellular functions, including proliferation, apoptosis and inflammation. The effector caspase-3 is also activated to complete apoptosis (18) . The present study results demonstrated that miR-1180 overexpression promoted cell apoptosis, suppressed the levels of NF-κB and Bcl-2, and increased the levels of Bax and Caspases-3. Therefore, miR-1180 may induce DU145 cell apoptosis through the NF-κB signaling pathway.
Metastasis is the leading cause of cancer-associated mortality, while cell invasion and migration are the most important biological characteristics of malignant tumors (19) . In the present study, wound healing and transwell assays were performed to observe the effect of miR-1180 on the migration and invasion of DU145 cells. The results demonstrated that overexpression of miR-1180 suppressed the cell migration and invasion. Thus, it was confirmed that miR-1180 may function as a tumor suppressor in prostate cancer.
TRAF1 is a protein associates with the signal transduction from various receptors of the TNF receptor superfamily (20) . In addition, BAG2 promotes tumorigenesis through enhancing the mutant p53 protein levels and function, while it is also involved in cellular senescence by the p21/CIP1 pathway (21, 22) . The results reported in the present study indicated that overexpression of miR-1180 inhibited the levels of TRAF1 and BAG2 mRNA and protein. Bioinformatics analysis and dual-luciferase reporter assay further verified that TRAF1 and BAG2 are direct targets of miR-1180.
In conclusion, the present study confirmed that miR-1180 is associated with growth and apoptosis in prostate cancer by TRAF1 and BAG2 expression regulation and NF-κB signaling pathway activation. Therefore, miR-1180 may be a potential tumor suppressor in prostate cancer.
